<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[Ischemia]]></title>
    <link>https://www.leadingmarketresearch.com/pharmaceuticals-biotechnology/pharmaceuticals/diseases-conditions/ischemia</link>
    <description><![CDATA[Ischemia]]></description>
    <pubDate>Sat, 11 Jul 2026 18:44:19 +0000</pubDate>
    <generator>Zend_Feed</generator>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <item>
      <title><![CDATA[Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update]]></title>
      <link>https://www.leadingmarketresearch.com/ischemia-reperfusion-injury-drugs-in-development-by-stages-target-moa-ro</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.<br><br>Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging. <br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provide...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-222238"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 08 Apr 2022 11:35:28 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Myocardial Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update]]></title>
      <link>https://www.leadingmarketresearch.com/myocardial-ischemia-drugs-in-development-by-stages-target-moa-roa-molec</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape.<br><br>Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history. <br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare lat...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-222320"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 08 Apr 2022 11:35:28 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Critical Limb Ischemia - Pipeline Review, H1 2020]]></title>
      <link>https://www.leadingmarketresearch.com/critical-limb-ischemia-pipeline-review-h1-2020</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2020, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.<br><br>Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival. <br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-214879"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Thu, 07 May 2020 13:13:49 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Ischemia Global Clinical Trials Review, H2, 2019]]></title>
      <link>https://www.leadingmarketresearch.com/ischemia-global-clinical-trials-review-h2-2019</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>GlobalData&#039;s clinical trial report, “Ischemia Global Clinical Trials Review, H2, 2019&quot; provides an overview of Treatment Ischemia clinical trials scenario. This report provides top line data relating to the clinical trials on Ischemia . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. <br><br>The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantag...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-213665"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Mon, 24 Feb 2020 15:56:48 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Critical Limb Ischemia - Pipeline Review, H2 2019]]></title>
      <link>https://www.leadingmarketresearch.com/critical-limb-ischemia-pipeline-review-h2-2019</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2019, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.<br><br>Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival. <br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-212626"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 11 Dec 2019 11:13:09 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Ischemia Reperfusion Injury - Pipeline Review, H1 2019]]></title>
      <link>https://www.leadingmarketresearch.com/ischemia-reperfusion-injury-pipeline-review-h1-2019</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H1 2019, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.<br><br>Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging. <br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analys...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-208026"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 26 Mar 2019 12:29:57 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Critical Limb Ischemia - Market Insights, Epidemiology and Market Forecast-2023]]></title>
      <link>https://www.leadingmarketresearch.com/critical-limb-ischemia-market-insights-epidemiology-and-market-forecast</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;">Note*: This report requires 5-10 business days to complete.

DelveInsight’s Critical Limb Ischemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Critical Limb Ischemia forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Critical Limb Ischemia till 2023. 


Key Coverage and Benefits

• The report will help in developing business strategies by understanding the trends shaping and driving the global Critical Limb Ischemia market. 
• Identifying patient populations in the global “Critical Limb Ischemiamarket to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Critical Limb Ischemia therapeutics in ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-195179"><span class="price">$4,950.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 25 Apr 2017 20:08:12 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Acute Ischemic Stroke Global Clinical Trials Review, H1, 2017]]></title>
      <link>https://www.leadingmarketresearch.com/acute-ischemic-stroke-global-clinical-trials-review-h1-2017</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>GlobalData&#039;s clinical trial report, “Acute Ischemic Stroke Global Clinical Trials Review, H1, 2017&quot; provides an overview of Acute Ischemic Stroke clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Ischemic Stroke. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.<br><br>The report enhances the decision making capabilities and helps to create an effective counter strategies t...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-193228"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 07 Apr 2017 11:35:17 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Ischemia Reperfusion Injury - Pipeline Review, H2 2016]]></title>
      <link>https://www.leadingmarketresearch.com/ischemia-reperfusion-injury-pipeline-review-h2-2016</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct’s, ‘Ischemia Reperfusion Injury - Pipeline Review, H2 2016’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape. <br><br>The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. <br><br>Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial re...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-184528"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Thu, 15 Sep 2016 21:22:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Critical Limb Ischemia Global Clinical Trials Review, H2, 2016]]></title>
      <link>https://www.leadingmarketresearch.com/critical-limb-ischemia-global-clinical-trials-review-h2-2016</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>GlobalData&#039;s clinical trial report, “Critical Limb Ischemia Global Clinical Trials Review, H2, 2016&quot; provides an overview of Critical Limb Ischemia clinical trials scenario. This report provides top line data relating to the clinical trials on Critical Limb Ischemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.<br><br>The report enhances the decision making capabilities and helps to create an effective counter strategie...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-184420"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Thu, 15 Sep 2016 20:23:57 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Ischemia Reperfusion Injury Global Clinical Trials Review, H2, 2016]]></title>
      <link>https://www.leadingmarketresearch.com/ischemia-reperfusion-injury-global-clinical-trials-review-h2-2016</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>GlobalData&#039;s clinical trial report, “Ischemia Reperfusion Injury Global Clinical Trials Review, H2, 2016&quot; provides an overview of Ischemia Reperfusion Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Ischemia Reperfusion Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.<br><br>The report enhances the decision making capabilities and helps to create an effective co...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-184430"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Thu, 15 Sep 2016 20:23:57 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Ischemic Cardiomyopathy Global Clinical Trials Review, H2, 2016]]></title>
      <link>https://www.leadingmarketresearch.com/ischemic-cardiomyopathy-global-clinical-trials-review-h2-2016</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>GlobalData&#039;s clinical trial report, “Ischemic Cardiomyopathy Global Clinical Trials Review, H2, 2016&quot; provides an overview of Ischemic Cardiomyopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Ischemic Cardiomyopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.<br><br>The report enhances the decision making capabilities and helps to create an effective counter strate...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-184431"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Thu, 15 Sep 2016 20:23:57 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Acute ischemic stroke (AIS)- Market Insights, Epidemiology and Market Forecast-2023]]></title>
      <link>https://www.leadingmarketresearch.com/acute-ischemic-stroke-ais-market-insights-epidemiology-and-market-forec</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;">
Note*: This report requires 7-10 business days to complete.
DelveInsight’s Acute ischemic stroke (AIS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Acute ischemic stroke (AIS) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Acute ischemic stroke (AIS) till 2023. 


Key Coverage and Benefits

• The report will help in developing business strategies by understanding the trends shaping and driving the global Acute ischemic stroke (AIS) market. 
• Identifying patient populations in the global “Acute ischemic stroke (AIS)market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Acute ischem...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-183878"><span class="price">$4,950.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 24 Aug 2016 13:19:26 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Critical Limb Ischemia - Pipeline Review, H1 2016]]></title>
      <link>https://www.leadingmarketresearch.com/critical-limb-ischemia-pipeline-review-h1-2016</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct’s, ‘Critical Limb Ischemia - Pipeline Review, H1 2016’, provides an overview of the Critical Limb Ischemia pipeline landscape. <br><br>The report provides comprehensive information on the therapeutics under development for Critical Limb Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. <br><br>Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conference...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-177858"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 17 Jun 2016 09:15:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Brain Ischemia - Pipeline Review, H1 2016]]></title>
      <link>https://www.leadingmarketresearch.com/brain-ischemia-pipeline-review-h1-2016</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct’s, ‘Brain Ischemia - Pipeline Review, H1 2016’, provides an overview of the Brain Ischemia pipeline landscape. <br><br>The report provides comprehensive information on the therapeutics under development for Brain Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Brain Ischemia and features dormant and discontinued projects. <br><br>Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor present...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-174148"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 31 May 2016 09:45:03 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Myocardial Ischemia - Pipeline Review, H1 2016]]></title>
      <link>https://www.leadingmarketresearch.com/myocardial-ischemia-pipeline-review-h1-2016</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct’s, ‘Myocardial Ischemia - Pipeline Review, H1 2016’, provides an overview of the Myocardial Ischemia pipeline landscape. <br><br>The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. <br><br>Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filin...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-173845"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Sat, 28 May 2016 19:12:44 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Ischemia Reperfusion Injury - Pipeline Review, H1 2016]]></title>
      <link>https://www.leadingmarketresearch.com/ischemia-reperfusion-injury-pipeline-review-h1-2016</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct’s, ‘Ischemia Reperfusion Injury - Pipeline Review, H1 2016’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape. <br><br>The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. <br><br>Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial re...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-173868"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Sat, 28 May 2016 19:12:44 +0000</pubDate>
    </item>
  </channel>
</rss>
